APT Pharmaceutical LLC Closes New $22 Million Funding Round
Published: Oct 04, 2007
BURLINGAME, CA--(Marketwire - October 04, 2007) - APT Pharmaceuticals, a specialty drug development company focused on effective treatments for significant unmet medical needs, announced today that it has closed a $22 million Series A-2 round of financing. New investors Versant Ventures and Great Point Partners joined existing firms Vivo Ventures and Charter Life Sciences in the round. Coinciding with the funding, Camille Samuels, Managing Director, Versant Ventures and David Kroin, Managing Director, Great Point Partners have joined the APT board.